Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials

Accounts of Chemical Research

Volumn 36, Issue 6, 2003, Pages 417-425

  Meijer, Laurent ^a,b   Raymond, Eric ^c  

^a STATION BIOLOGIQUE   (France)

^b ROCKEFELLER UNIVERSITY   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYETHYLAMINO 6 BENZYLAMINO 9 METHYLPURINE; 6 N (3,3 DIMETHYLALLYL)ADENINE; 6 N,N DIMETHYLADENINE; 6 O CYCLOHEXYLMETHYLGUANINE; AMINOPURVALANOL; CYCLIN B; CYCLIN DEPENDENT KINASE 1; H 717; MDL 108522; NU 6102; OL 567; OLOMOUCINE; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PURINE DERIVATIVE; PURVALANOL; PURVALANOL A; PURVALANOL B; ROSCOVITINE; STAUROSPORINE; UNCLASSIFIED DRUG;

ASTERIAS; CANCER; CARDIOVASCULAR DISEASE; CELL CYCLE; CELL DIVISION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG IDENTIFICATION; DRUG POTENTIATION; ENZYME ACTIVATION; GLOMERULONEPHRITIS; HUMAN; NONHUMAN; OOCYTE; PROTOZOAL INFECTION; REVIEW; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; OOCYTES; PHOSPHOTRANSFERASES; PURINES; STARFISH;

EID: 0037665145     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar0201198     Document Type: Review

References (61)

1. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315.
2. Meijer, L. Hormonal control of oocyte maturation in Arenicola marina L. (Annelida Polychaeta). I. Morphological study of oocyte maturation. Dev. Growth Differ. 1979, 21, 303-314.
3. Meijer, L.; Paul M.; Epel D. Stimulation of protein phosphorylation during fertilization-induced maturation of Urechis caupo oocytes. Dev. Biol. 1982, 94, 62-70.
4. Meijer, L.; Guerrier, P. Maturation and Fertilization in starfish oocytes. Int. Rev. Cytol. 1984, 86, 129-196.
5. Meijer, L.; Pondaven, P.; Guerrier, P.; Moreau, M. A starfish oocyte user's guide. Cah. Biol. Mar. 1986, 25, 457-480.
6. Meijer, L.; Mordret, G. Starfish oocyte maturation: from prophase to metaphase. Semin. Dev. Biol. 1994, 5, 165-171.
7. Kanatani, H.; Shirai, H.; Nakanishi, K.; Kurokawa, T. Isolation and identification of meisosis inducing substance in starfish Asterias amurensis. Nature 1969, 221, 273-274.
8. Okumura, E.; Fukuhara, T.; Yoshida, H.; Hanada, S. S.; Kozutsumi, R.; Mori, M.; Tachibana, K.; Kishimoto, T. Akt inhibits Myt1 in the signaling pathway that leads to meiotic G2/M-phase transition. Nat. Cell Biol. 2002, 4, 111-116.
9. Pondaven, P.; Meijer, L. Protein phosphorylation and oocyte maturation. I. Induction of starfish oocyte maturation by intracellular microinjection of a phosphatase inhibitor, α-naphthylphosphate. Exp. Cell Res. 1986, 163, 477-488.
10. Meijer, L.; Pondaven, P.; Tung, H. Y. L.; Cohen, P.; Wallace, R. W. Protein phosphorylation and oocyte maturation. II. Inhibition of starfish oocyte maturation by intracellular microinjection of protein phosphatases-1 and -2A and alkaline phosphatase. Exp. Cell Res. 1986, 163, 489-499.
11. Pelech, S. L.; Meijer, L.; Krebs, E. G. Characterization of maturation-activated histone H1 and ribosomal S6 kinases in sea star oocytes. Biochemistry 1987, 26, 7960-7968.
12. Meijer, L.; Pelech, S. L.; Krebs, E. G. Differential regulation of histone H1 and ribosomal S6 kinases during sea star oocyte maturation. Biochemistry 1987, 26, 7968-7974.
13. 1 kinase: evidence for identity with MPF. Cell 1988, 55, 371-378.
14. Meijer, L.; Arion, D.; Golsteyn, R.; Pines, J.; Brizuela, L.; Hunt, T.; Beach, D. Cyclin is a component of the sea urchin egg M-phase specific histone H1 kinase. EMBO J. 1989, 8, 2275-2282.
15. cdc2 and cyclin components. Genes Dev. 1990, 4, 9-17.
16. Masui, Y. A quest for cytoplasmic factors that control the cell cycle. Prog. Cell Cycle Res. 1996, 2, 1-13.
17. Kishimoto, T. Activation of MPF at meiosis reinitiation in starfish oocytes. Dev. Biol. 1999, 214, 1-8.
18. Labbe, J. C.; Capony, J. P.; Caput, D.; Cavadore, J. C.; Derancourt, J.; Kaghad, M.; Lelias, J. M.; Picard, A.; Doree, M. MPF from starfish oocytes at first meiotic metaphase is a heterodimer containing one molecule of cdc2 and one molecule of cyclin B. EMBO J. 1989, 8, 3053-3058.
19. suc1-coated microtitration plates. Anticancer Res. 1991, 11, 1581-1590.
20. Rebhun, L. I.; White, D.; Sander, G.; Ivy, N. Cleavage inhibition in marine eggs by puromycin and 6-dimethylaminopurine. Exp. Cell Res. 1973, 77, 312-318.
21. Meijer, L.; Pondaven, P. Cyclic activation of histone H1 kinase during the sea urchin egg mitotic divisions. Exp. Cell Res. 1988, 174, 116-129.
22. Neant, I.; Guerrier, P. 6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. Exp. Cell Res. 1988, 176, 68-79.
23. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J. Y.; Détivaud, L.; Leclerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine derivatives. Eur. J Biochem. 1994, 224, 771-786.
24. Parker, C. W., Entsch, B.; Letham, D. Inhibitors of two enzymes which metabolize cytokinins. Phytochemistry 1986, 25, 303-310.
25. Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
26. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J. P. J.; Blow, J. J.; Inagaki, N.; Inagaki, M.; Delcros, J. G.; Moulinoux, J. P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997, 243, 527-536.
27. Gray, N.; Wodicka, L.; Thunnissen, A. M.; Norman, T.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; Leclerc, S.; Meijer, L.; Kim, S. H.; Lockhart, D. J.; Schultz, P. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors. Science 1998, 281, 533-538.
28. Rosania, G. R.; Merlie, J. Jr.; Gray, N.; Chang, Y. T.; Schultz, P. G.; Heald, R. A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4797-4802.
29. Chang, Y. T.; Gray, N. G.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
30. Legraverend, M.; Ludwig, O.; Bisagni, E.; Leclerc, S.; Meijer, L. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett. 1998, 8, 793-798.
31. Legraverend, M.; Noble, M.; Tunnah, P.; Ducrot, P.; Ludwig, O.; Leclerc, S.; Grierson, D. S.; Meijer, L.; Endicott, J. Cyclin-dependent kinase inhibition by new C-2 alkylynated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 2000, 43, 1282-1292.
32. Haesslein, J. L.; Jullian, N. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future. Curr. Top. Med. Chem. 2002, 2, 1035-1048.
33. De Bondt, H. L.; Rosenblatt, J.; Jancarik, J.; Jones, H. D.; Morgan, D. O.; Kim, S. H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363, 595-602.
34. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S. H. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins: Struct. Funct. Genet. 1995, 22, 378-391.
35. Dreyer, M. K.; Borcherding, D. R.; Dumont, J. A.; Peet, N. P.; Tsay, J. T.; Wright, P. S.; Bitonti, A. J.; Shen, J.; Kim, S. H. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 2001, 44, 524-530.
36. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E.; Tucker, J. A.; Wang, L.; Whitfield, H. J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 2002, 9, 745-749.
37. Gray, N.; Détivaud, L.; Doerig, C.; Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6, 859-876.
38. Hardcastle, I. R.; Golding, B. T.; Griffin, R. J. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 325-348.
39. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
40. Wang, D.; de La Fuente, C.; Deng, L.; Wang, L.; Zilberman, I.; Eadie, C.; Healey, M.; Stein, D.; Denny, T.; Harrison, L. E.; Meijer, L.; Kashanchi, F. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 2001, 75, 7266-7279.
41. Schang, L. M.; Bantly, A.; Knockaert, M.; Shaheen, F.; Meijer, L.; Malim, M. H.; Gray, N. S.; Schaffer, P. A. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of Herpes simplex virus and Human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J. Virol. 2002, 76, 7874-7882.
42. Wang, Z.; Canagarajah, B. J.; Boehm, J. C., Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
43. Knockaert, M.; Gray, N.; Damiens, E.; Chang, Y. T.; Grellier, P.; Grant, K.; Fergusson, D.; Mottram, J.; Soete, M.; Dubremetz, J. F.; LeRoch, K.; Doerig, C.; Schultz, P. G.; Meijer, L. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised ligants. Chem. Biol. 2000, 7, 411-422.
44. Knockaert, M.; Lenormand, P.; Gray, N.; Schultz, P.; Pouyssegur, J.; Meijer, L. p42/p44MAPKS are intracellular targets of the CDK inhibitor purvalanol. Oncogene 2002, 21, 6413-6424.
45. Knockaert, M.; Viking: K.; Schmitt, S.; Leost, M.; Mottram, J.; Kunick, C.; Meijer, L. Intracellular targets of paullones: identification by affinity chromatography using immobilized inhibitor. J. Biol. Chem. 2002, 277, 25493-25501.
46. Knockaert, M.; Meijer, L. Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. Biochem. Pharmacol. 2002, 64, 819-825.
47. Abraham, R. T.; Acquarone, M.; Andersen, A.; Asensi, A.; Bellé, R.; Berger, F.; Bergounioux, C.; Brunn, G.; Buquet-Fagot, C.; Fagot, D.; Glab, N.; Goudeau, H.; Goudeau, M.; Guerrier, P.; Houghton, P. J.; Hendriks, H.; Kloareg, B.; Lippai, M.; Marie, D.; Maro, B.; Meijer, L.; Mester, J.; Mulner-Lorillon, O.; Poulet, S. A.; Schierenberg, E.; Schutte, B.; Vaulot, D.; Verlhac, M. H. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol. Cell 1995, 83, 105-120.
48. Alessi, F.; Quarta, S.; Savio, M.; Riva, F.; Stivala, L. A.; Scovassi, A. I.; Meijer, L.; Prosperi, E. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by inhibition of CDK2 kinase activity. Exp. Cell Res. 1998, 245, 8-18.
49. Villerbu, N.; Gaben, A. M.; Redeuilh, G.; Mester, J. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int. J. Cancer 2002, 97, 761-769.
50. Mihara, M.; Shintani, S.; Kiyota, A.; Matsumura, T.; Wong, D. T. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int. J. Oncol. 2002, 21, 95-101.
51. Edamatsu, H.; Gau, C. L.; Nemoto, T.; Guo, L.; Tamanoi, F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyl-transferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 2000, 19, 3059-3068.
52. O'Connor, D. S.; Wall, N. R.; Porter, A. C.; Altieri, D. C. A p34-(cdc2) survival checkpoint in cancer. Cancer Cell 2002, 2, 43-54.
53. Matushansky, I.; Radparvar, F.; Skoultchi, A. I. Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 14317-14322.
54. Borgne, A.; Golsteyn, R. The role of cyclin dependent kinases in apoptosis. In "Cell Cycle Regulators as Therapeutic Targets" (L. Meijer, A. Jézéquel and M. Roberge, Eds.), Prog. Cell Cycle Res., in press.
55. Sandal, T.; Stapnes, C.; Kleivdal, H.; Hedin, L.; Doskeland, S. O. A novel extraneuronal role for cyclin-dependent protein kinase 5 (CDK5). J. Biol. Chem. 2002, 277, 20783-20793.
56. Adachi, S.; Obaya, A. J.; Han, Z.; Ramos-Desimone, N.; Wyche, J. H.; Sedivy, J. M. c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle. Mol. Cell. Biol. 2001, 21, 4929-4937.
57. Castedo, M.; Roumier, T.; Blanco, J.; Ferri, K. F.; Barretina, J.; Tintignac, L. A.; Andreau, K.; Perfettini, J. L.; Amendola, A.; Nardacci, R.; Leduc, P.; Ingber, D. E.; Druillennec, S.; Roques, B.; Leibovitch, S. A.; Vilella-Bach, M.; Chen, J.; Este, J. A.; Modjtahedi, N.; Piacentini, M.; Kroemer G. Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J. 2002, 21, 4070-4080.
58. McClue, S. J.; Blake, B.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P. M.; MacKenzie, M.; Melville, J.; Stewart, K.; Wang, S.; Zhelev, N.; Zheleva, N.; Lane, D. P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer., in press.
59. Shum, P. W.; Peet, N. P.; Weintraub, P. M.; Le, T. B.; Zhao, Z.; Barbone, F.; Cashman, B.; Tsay, J.; Dwyer, S.; Loos, P. C.; Powers, E. A.; Kropp, K.; Wright, P. S.; Bitonti, A.; Dumont, J.; Borcherding, D. R. The design and synthesis of purine inhibitors of CDK2. III. Nucleos. Nucleot. Nucl. Acids 2001, 20, 1067-1078.
60. Pippin, J. W.; Qu, Q.; Meijer, L.; Shankland, S. J. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel CDK2 antagonist. J. Clin. Invest. 1997, 100, 2512-2520.
61. Clough, J. CDK inhibitor shows promise for inflammatory kidney disease. Drug Discovery Today 2002, 7, 789-790.